

ASX RELEASE

Volpara Quarterly Results and Strategic Update Webinar Notification

Wellington, NZ, 19 July 2022: [Volpara Health Technologies](#) (“Volpara,” “the Group,” or “the Company”; ASX: VHT), a global leader in software for the early detection of breast cancer, will be hosting an investor webinar on **Thursday 28th July 2022** at 9:00am AEST (Sydney/Melbourne), 11:00am NZST (Auckland/Wellington) to update shareholders following the release of its quarterly financial results and the outcomes of its recently completed strategic review.

The call will be hosted by Teri Thomas, Chief Executive Officer, Craig Hadfield, Chief Financial Officer and Jill Spear, Executive Vice President of Sales and Marketing

Webinar details

Date: Thursday 28th July 2022
Time: 9:00am AEST (Sydney/Melbourne), 11:00am NZST (Auckland/Wellington)
To register: https://us02web.zoom.us/webinar/register/WN_05qYLGmFT5WrEyYXM9OxOQ
Dial in details: Will be provided to you upon registration

Participants will be able to submit questions during the webinar via a written Q&A facility displayed at the bottom of the webinar screen or can submit them in advance to hhowlett@we-worldwide.com.

Authorisation & Additional Information

This announcement was authorised by the Group CEO of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Teri Thomas, CEO
Volpara Health Technologies
Teri.thomas@volparahealth.com
t: +64 4 499 6029

Hannah Howlett
WE Communications
hhowlett@we-worldwide.com
t: +61 4 5064 8064

About Volpara Health Technologies Limited (ASX: VHT)

Volpara Health Technologies is a global leader in the research and development of artificial intelligence for the early detection of breast cancer. Volpara's software provides clinicians feedback on breast density, compression, dose, and quality, enabling them to offer their patients personalised breast care and enhanced risk assessment.

Founded in 2009 on research originally conducted at the University of Oxford, Volpara has seen its technology and services used by customers and/or research projects in 40 countries.

Volpara's ground-breaking work is supported by 100 patents, over 200 peer-reviewed publications, the most rigorous security certifications, and numerous trademarks and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, Volpara has raised A\$132 million. With offices in Seattle and Boston, Volpara is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com.